Initial therapy before surgery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial looks at how well certain initial treatments (like targeted therapy, immunotherapy, or liver-directed procedures) work in people with liver cancer who have not had surgery yet. It aims to see if these treatments can shrink the tumor enough to allow removal later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer.
- Your first treatment was one of these: chemotherapy through a liver artery (HAIC), blocking blood supply to the tumor (TACE), targeted pills (TKIs), immunotherapy (ICIs), or radiation therapy.
- You are able to carry out normal daily activities or only limited in strenuous activity (ECOG score 0 or 1).
- Your liver function is relatively good (Child-Pugh score 5 to 7, meaning mild to moderate liver damage).
- You have not had any other cancer in the last 5 years.
- You have complete medical records and have been followed for at least 3 months after treatment started.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This trial tests a combination of treatments before and after surgery for liver cancer that can be removed. The goal is to see if adding targeted therapy and immunotherapy can reduce the risk of cancer coming back.
This trial tests whether combining radiation (IMRT) with two drugs—camrelizumab (an immunotherapy) and apatinib (a targeted therapy)—before surgery can help people with liver cancer that has spread to the main blood vessel of the liver (portal vein). The goal is to shrink the tumor and improve surgical outcomes.
This study tests a combination of treatments to shrink liver cancer that cannot be removed with surgery at first. The goal is to make the tumor small enough for surgery or to disappear completely, and then either have surgery or continue the treatment.
This trial tests giving chemotherapy directly into the liver artery (HAIC) combined with immunotherapy before surgery for liver cancer that can be removed but is too large or numerous for standard treatment. The goal is to shrink the tumor and improve surgery results.
This trial tests if giving a combination of drugs (apatinib and camrelizumab) along with a procedure called TACE before surgery can help treat a certain type of liver cancer. The goal is to shrink the tumor before the operation to improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.